I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

EURETINA 2023

-
Coming soon
08:30 AM
Duration 4mins Virtual
An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Gallego-Pinazo R, Weng, C, Souverain A, Stoilov I, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Faricimab▼ Rapidly Improves Fluid Parameters in Patients With nAMD
Gale R, London N, Kotecha A, Willis J, Souverain A, Shildkrot E, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Baseline characteristics and 3 month data from patients receiving faricimab▼ for nAMD or DME in the real-world VOYAGER study
Sheth V, Bailey C, Bengus M, Chaikitmongkol V, Chaudhary V, Chi G, Finger R, Gallego R, Gilberg R, Koh A, Ishida S, Lövestam M, Parravano M, Luna Pinto JD, Scheidl S, Schmitz-Valckenberg MS, Souied E, Guymer R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Burden in the Clinical Management of Diabetic Macular Edema: A Multicenter Analysis in the UK
Peto T, Chen X, Talks S, Menon G, Ghanchi F, Shah P, Yang Q, Ferrara D, Adesanya L, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Changes in Intraocular Ang-2 and VEGF-A Following Faricimab▼ Treatment in nAMD and DME
Cheung G, Bogman K, Diack C, Stoilov I

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Deep learning segmentation of foveal avascular zone in optical coherence tomography angiography of nonproliferative diabetic retinopathy
Benmansour F, Camino A, Wang Z, Basu Bal A, Carano R, Ferrara D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Fibrosis Characterisation and Prevention in nAMD: Identification of Subretinal Triggers, Cell Types Responsible and Inhibitors Using Improved Tools
Westenskow P, Ozaki E, Doyle S, Roubeix C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Personalised Faricimab▼ Dosing Increased the Proportion of Patients With nAMD Achieving Q16W Dosing in Year 2 of TENAYA/LUCERNE, While Maintaining Functional and Anatomical Outcomes
Ambresin A, Kotecha A, Willis J, Souverain A, Shildkrot E, Swaminathan B, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Efficacy, durability, and safety of faricimab▼ in neovascular age-related macular degeneration (nAMD): 48-week results from the China subpopulation of the phase 3 LUCERNE trial
Chen Y, Kotecha A, Willis J, Liu R, Li S, Zhang L, Zhang M, Sun D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Port Delivery System With Ranibizumab in Patients With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pavilion Trial
Wykoff C, Chang M, Emanuelli A, Holekamp N, Latkany P, Malhotra V, Brittain C, Howard D, Santhanakrishnan A, Wetzel-Smith M, Quezada-Ruiz C, Pieramici D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Postoperative Monitoring and Long-term Follow-up: A PDS-treated Patient Case From the Ladder Phase 2 Trial Continuing into the Portal Extension Trial
Graff J, Heinrich D, Blotner S, Cavichini Cordeiro M, Gune S, Singh N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Refill-Exchange Procedure for the Port Delivery System with Ranibizumab: Optimisation and Enhanced Training
Becker M, Colina J, Graff J, Kitchens J, Thompson J, Malhotra V, Menezes A, Patel S, Singh N, Utley S, Vicente A, Jaycock P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
FARWIDE-DME: early treatment patterns of faricimab▼ among DME patients in the UK
Bailey C, Peto T, Downey L, Kiire C, Pearce I, Reynolds R, Sivaprasad S, Chi G, James N, Downey A, Shah P, Dodds M, Dayal P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Visual Loss in Geographic Atrophy: A Comprehensive Exploratory Analysis of Function and Morphology From the Lampalizumab Trial Programme
Ferrara D, Anegondi N, Steffen V, Chakravarthy U

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 4mins Virtual
Investigating the Burden of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Treatment on Recipients and Caregivers in North America and Europe
Gale R, Tabano D, Cox O, Garmo V, Ahmed A, Hill S, Patel N, Watane A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:19 PM
Duration 6mins Emerald Room
Comparative Efficacy of Faricimab▼ for the Treatment of Diabetic Macular Edema: A Systematic Literature Review and Network Meta-Analysis
Holekamp N, Mar F, Gibson K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:07 AM
Duration 6mins Room E102
The Relevance of Clinical and Imaging Features in Artificial Intelligence-Based Prediction of Geographic Atrophy Progression
Ferrara D, Cluceru J, Slama O, Anegondi N, Gao S, Friesenhahn M, Rabe C

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:16 AM
Duration 5mins Speakers Corner
Socio-economic deprivation and diabetic macular edema: health equity improvements driven by faricimab in an aggregate distributional cost-effectiveness analysis from an English NHS perspective
Gale R, Meunier A, Opeifa O, Longworth L, Cox O, Buhrer C, Durand-Zaleski I, Kelly S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:07 AM
Duration 6mins Room E102
Port Delivery System With Ranibizumab in Diabetic Macular Edema: Primary Analysis Results of the Phase 3 Pagoda Trial
Graff J, Marcus D, Campochiaro P, Rahman S, Malhotra V, Latkany P, Gune S, DeGraaf S, Bobbala A, Rabena M, Quezada-Ruiz C, Khanani A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:13 AM
Duration 6mins Room E102
FARETINA-DME-six-month treatment patterns and outcomes in patients with diabetic macular edema treated with faricimab▼: an IRIS (tm) Registry analysis
Bailey C, Tabano D, Borkar D, Garmo V, Ahmed A, Myers R, LaPrise A, Ali F, Leng T, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:19 AM
Duration 6mins Room E102
Automated Segmentation of Hyperreflective Foci in DME Shows Greater Volume Reduction in Eyes Treated With Faricimab▼ Compared to Aflibercept in the Phase 3 YOSEMITE and RHINE Clinical Trials
Chakravarthy U, Maunz A, Von Schulthess E, Patel K, Bachmeier I, Jones I, Cohen Y, Gibson K, Willis J, Glittenberg C, Fauser S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:18 PM
Duration 6mins Grand Auditorium
The Potential for Q20W Dosing With Faricimab▼ and Extended Treatment Outcomes in Neovascular Age-Related Macular Degeneration: a Post Hoc Analysis of the Pivotal TENAYA/LUCERNE Trials
Ambresin A, Koh A, Singer M, Tadayoni R, Hill L, Souverain A, Kotecha A, Margaron P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
01:03 PM
Duration 6mins E102
Optimisation of the Port Delivery System with Ranibizumab (PDS): Key Steps and Impact on Patient Outcomes
Hillier R, Vicente A, Jaycock P, Quezada-Ruiz C, Singh N

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:46 PM
Duration 6mins Room E102
Faricimab▼ Personalised Treat-and-Extend–Based Dosing Dynamics in Patients With DME
Figueroa M, Pearce I, Lim J, Gibson K, Jain N, Souverain A, Yang M, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
09:25 AM
Duration 6mins Room E102
Faster Time to Retinal Fluid Control With Faricimab▼ vs Aflibercept in Patients With DME in the Phase 3 YOSEMITE/RHINE Trials – Lanzetta P
Lanzetta P, Rachitskaya A, Camino A, Gibson K, Mar F, Shildkrot E, Tang Y, Willis J, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 6mins Room E102
Faricimab▼ Reduces Macular Leakage vs Aflibercept in Patients With Diabetic Macular Edema
Sivaprasad S, Kolomeyer A, Nudleman E, Csaky K, Willis J, Gibson K, Wang T, Haskova Z, Amador M, Mar F, Goldberg R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:19 PM
Duration 6mins Room E102
A novel intravitreal anti-IL-6 monoclonal antibody for uveitic macular edema (UME): preliminary results from the phase 1 DOVETAIL study
Pavesio C, Sharma S, Suhler E, Lin P, Pauly-Evers M, Willen D, Peck R, Storti F, Rauhut S, Gott T, Passemard B, Macgregor L, Haskova Z, Silverman D, Fauser S, Mesquida M

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
12:36 PM
Duration 5mins Speakers Corner
FARWIDE-nAMD: early treatment patterns of faricimab▼ among neovascular age-related macular degeneration (nAMD) patients in the UK
Talks J, De Salvo G, Patel P, de Silva S, Gale R, Varma D, McKibbin M, James N, Downey A, Shah P, Dodds M, Dayal P, Chi G

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:30 PM
Duration 6mins E103/104
Pharmacokinetic Profile of the Port Delivery System With Ranibizumab in the Phase 3 Pagoda Trial of Diabetic Macular Edema and the Phase 3 Pavilion Trial of Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
Dhoot D, Ding HT, Hyung S, Latkany P, Maass K, Rahman S, Hsu J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
03:43 PM
Duration 6mins Room E103/104
Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial
Li X, Sun X, Jiang Q, Liu X, Idowu O, Liu R, Liu W, Tang Y, Willis J, Zhang L, Kotecha A

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar